Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.

Mirvetuximab soravtansine is an antibody-drug conjugate comprising a folate receptor-alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. The randomized, open label, phase III study FORWARD I compared mirvetuximab soravtansine and investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian cancer (EOC).Eligible patients with 1-3 prior lines of therapy and whose tumors were positive for FRα expression were randomly assigned, in a 2:1 ratio, to receive mirvetuximab soravtansine (6 mg/kg, adjusted ideal body weight) or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). The primary endpoint was progression-free survival (PFS, RECIST version 1.1, blinded independent central review) in the intention-to-treat (ITT) population and in the prespecified FRα high population.A total of 366 patients were randomized; 243 received mirvetuximab soravtansine and 109 received chemotherapy. The primary endpoint, PFS, did not reach statistical significance in either the ITT (hazard ratio [HR], 0.98, P = 0.897) or the FRα high population (HR, 0.69, P = 0.049). Superior outcomes for mirvetuximab soravtansine over chemotherapy were observed in all secondary endpoints in the FRα high population including improved objective response rate (24% v 10%), CA-125 responses (53% v 25%), and patient reported outcomes (27% v 13%). Fewer treatment-related grade 3 or higher adverse events (25.1% v 44.0%), and fewer events leading to dose reduction (19.8% v 30.3%) and treatment discontinuation (4.5% v 8.3%) were seen with mirvetuximab soravtansine compared to chemotherapy.In patients with platinum-resistant EOC, mirvetuximab soravtansine did not result in a significant improvement in PFS compared with chemotherapy. Secondary endpoints consistently favored mirvetuximab soravtansine, particularly in patients with high FRα expression. Mirvetuximab soravtansine showed a differentiated and more manageable safety profile than chemotherapy.


View the full article @ Annals of oncology : official journal of the European Society for Medical Oncology


Get PDF with LibKey
Authors: K N Moore, A M Oza, N Colombo, A Oaknin, G Scambia, D Lorusso, G E Konecny, S Banerjee, C G Murphy, J L Tanyi, H Hirte, J A Konner, P C Lim, M Prasad-Hayes, B J Monk, P Pautier, J Wang, A Berkenblit, I Vergote, M J Birrer